Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Europe In-Vitro Diagnostics (IVD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering.
The Europe In-Vitro Diagnostics (IVD) Market was worth USD 23.35 billion in 2024 and is anticipated to reach USD 34.47 billion by 2033, growing at a CAGR of 4.42% during the period from 2025 to 2033. The market is fueled by the rising incidence of chronic and infectious diseases, improving healthcare awareness, and the development of diagnostic technologies. Aging populations in most European countries are also increasing the demand for early and precise disease detection.
Drivers of Growth in the Europe In-Vitro Diagnostics (IVD) Market
Aging Population and Increasing Chronic Diseases
Europe is witnessing tremendous demographic changes, with an increasing elderly population that is more prone to chronic diseases like diabetes, cardiovascular diseases, and cancer. This has generated a consistent demand for diagnostic tests to facilitate early detection, disease tracking, and therapy control. With an increase in life expectancy, the healthcare infrastructure is focusing on preventive care, with IVD having a critical function. Periodic blood testing, biomarker tests, and monitoring devices are being incorporated into periodic health checks, particularly in Germany and Italy, driving consistent growth in the IVD sector. Based on estimates by Eurostat, the percentage of individuals 65 and older in the EU's total population would increase from 21.1% (94.3 million) at the beginning of 2022 to 32.5% (136.1 million) in 2100.
Progress in Diagnostic Technology
Innovations in diagnostic technology, automation, and digitalization have substantially enhanced the accuracy, speed, and accessibility of IVD instruments. Europe has adopted these advances through strong investments in healthcare and the use of AI-driven diagnostics, next-generation sequencing (NGS), and high-throughput testing platforms. These technologies enable personalized medicine and allow healthcare professionals to make more rapid and educated treatment decisions. In addition, advances in laboratory automation and miniaturization have improved the efficiency of IVD testing, accelerating adoption in both clinical and home settings throughout Europe. In February 2023, bioMerieux SA introduced the MONKEYPOX R-GENE PCR kit for qualitative virus detection, marketed in countries accepting Research Use Only (RUO) products.
Government Support and Healthcare Infrastructure
Europe enjoys robust public health care systems and forward-thinking regulatory authorities that ensure access to diagnostic testing. EU-level programs to enhance the quality of healthcare, supplemented by reimbursement policies implemented at the country level, have fostered the extensive application of IVD products. Disease prevention, early detection, and health screening programs - particularly in cancer and infectious disease care - continue to drive market growth. Public health lab funding and collaborations with diagnostic firms have also grown, making Europe a leader in the implementation of new IVD solutions. December 2022, The European Investment Bank (EIB) has entered into a €20 million quasi-equity financing deal with Numares Health AG. The Regensburg company has created the AXINON system, a completely automated in-vitro diagnostics platform that improves diagnostic quality for chronic kidney, heart, liver disease, cancer, and multiple sclerosis.
Challenges in the Europe In-Vitro Diagnostics (IVD) Market
Complex Regulatory Environment
The EU In Vitro Diagnostic Regulation (IVDR) has raised scrutiny and regulatory complexity for manufacturers. Although directed towards safety and effectiveness, they call for further clinical data, stricter conformity testing, and notified body involvement. Small firms usually experience delays and higher costs to get new products to market. The change has also resulted in a temporary halt in product clearances and access to market, causing uncertainty for suppliers and healthcare providers wishing to implement the latest diagnostic technology.
High Costs and Reimbursement Limitations
Even with robust healthcare infrastructure, high costs related to sophisticated diagnostic equipment are still a deterrent for some European nations. Only some diagnostic tests are reimbursed by government-sponsored schemes, creating differences in access as well as adoption. The pressure of prices and budget limitations within the healthcare systems also acts as a deterrent to market growth, especially for newer and higher-priced technologies. Differences in reimbursement policies among EU member countries further complicate market entry for multinational IVD firms pursuing a single European strategy.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $23.35 Billion |
| Forecasted Market Value (USD) by 2033 | $34.47 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Europe |
Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamic
4.1 Growth Drivers
4.2 Challenges
5. Europe In-Vitro Diagnostics (IVD) Market
6. Market Share
6.1 By Test Types
6.2 By Products
6.3 By Application
6.4 By Technology
6.5 By End User
6.6 By Countries
7. Test Types
7.1 ELISA & CLIA
7.2 PCR
7.3 Rapid Test
7.4 Fluorescence Immunoassays (FIA)
7.5 In Situ Hybridization
7.6 Transcription Mediated Amplification
7.7 Sequencing
7.8 Colorimetric Immunoassay
7.9 Radioimmunoassay (RIA)
7.10 Isothermal Nucleic Acid Amplification Technology
7.11 Others
8. Products
8.1 Services
8.2 Instruments
8.3 Reagents
9. Applications
9.1 Infectious Disease
9.2 Diabetes
9.3 Cardiology
9.4 Oncology
9.5 Nephrology
9.6 Autoimmune Diseases
9.7 Drug Testing
9.8 Other Applications
10. Technologies
10.1 Immunoassay
10.2 Clinical Chemistry
10.3 Molecular Diagnostics/Genetics
10.4 Hematology
10.5 Microbiology
10.6 Coagulation
10.7 Others
11. End Users
11.1 Hospitals
11.2 Laboratories
11.3 Home-Care
11.4 Others
12. Country
12.1 Germany
12.2 France
12.3 Italy
12.4 Spain
12.5 Netherlands
12.6 Greece
12.7 Portugal
12.8 Belgium
12.9 Sweden
12.10 Austria
12.11 Denmark
12.12 Finland
12.13 Ireland
12.14 Luxembourg
12.15 Poland
12.16 Romania
12.17 Czechia
12.18 Hungary
12.19 Bulgaria
12.20 Slovakia
12.21 Croatia
12.22 Lithuania
12.23 Latvia
12.24 Slovenia
12.25 Estonia
12.26 Cyprus
12.27 Malta
12.28 Switzerland
12.29 Norway
12.30 Iceland
12.31 United Kingdom
12.32 Turkey
13. Porter's Five Forces
13.1 Bargaining Power of Buyer
13.2 Bargaining Power of Supplier
13.3 Threat of New Entrants
13.4 Rivalry among Existing Competitors
13.5 Threat of Substitute Products
14. SWOT Analysis
14.1 Strengths
14.2 Weaknesses
14.3 Opportunities
14.4 Threats
15. Company Analysis
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Danaher Corporation
- Thermo Fisher Scientific
- Sysmex Corporation
For more information about this report visit https://www.researchandmarkets.com/r/km2bco
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
